Intrinsiqq
CME Group Inc. logo

CME Group Inc. (CME) Insider Trading

Last 12 months

Insiders bought $667k and sold $30.1M on the open market.

3% of the selling was scheduled in advance under 10b5-1 plans. Chairman and CEO Terrence A Duffy sold $10.4M on May 15, 39% of their stake, outside a plan.

Net open-market
−$29.5M
4 buys · 14 sales
Under a 10b5-1 plan
3%
of the value sold
Insiders who bought / sold
1 / 10
executives and directors
Last open-market buy
Sep 2026
Sep 25, 2026

Get an email when CME's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

  • Oct 22No plan
    Martin J Gepsman
    Director · sold 400 at $302.50
    $121k
    1.6% of stake
  • Sep 25
    William R Shepard
    Director · bought 293 at $268.76
    $79k
    <0.1% of stake
  • Sep 14No plan
    Elizabeth A Cook
    Director · sold 500 at $280.11
    $140k
    2.7% of stake
  • Sep 10No plan
    Terrence A Duffy
    Chairman and CEO · sold 15,000 at avg $274.44
    $4.12M
    27% of stake
  • Jun 25
    William R Shepard
    Director · bought 339 at avg $230.57
    $78k
    0.1% of stake
  • May 18No plan
    Hilda Harris Piell
    Sr MD & Chief HR Officer · sold 5,753 at $304.63
    $1.75M
    17% of stake
  • May 15No plan
    Terrence A Duffy
    Chairman and CEO · sold 35,000 at avg $298.51
    $10.4M
    39% of stake
  • Mar 26
    William R Shepard
    Director · bought 1,470 at avg $297.38
    $437k
    0.6% of stake
  • Mar 1710b5-1 plan
    Jonathan L Marcus
    Sr MD General Counsel · sold 3,291 at $313.37
    $1.03M
    31% of stake
  • Mar 12No plan
    Ken Vroman
    Chief Transformation Officer · sold 5,160 at $309.00
    $1.59M
    26% of stake
  • Mar 6No plan
    Elizabeth A Cook
    Director · sold 1,000 at $320.00
    $320k
    5.3% of stake
  • Feb 23No plan
    Bryan T Durkin
    Director · sold 4,200 at $309.65
    $1.3M
    8.9% of stake
  • Feb 20No plan
    Martin J Gepsman
    Director · sold 300 at $305.90
    $92k
    1.2% of stake
  • Feb 6No plan
    Dennis Suskind
    Director · sold 748 at $300.00
    $224k
    22% of stake
  • Dec 30, 2025
    William R Shepard
    Director · bought 262 at avg $278.37
    $73k
    0.1% of stake
  • Dec 11, 2025No plan
    Terrence A Duffy
    Chairman and CEO · sold 25,000 at avg $269.55
    $6.74M
    28% of stake
  • Nov 20, 2025No plan
    Derek Sammann
    Sr MD Gl Hd Commodities Mkts · sold 7,200 at avg $275.67
    $1.98M
    14% of stake
  • Nov 3, 2025No plan
    Harold Eugene Ford Jr.
    Director · sold 1,000 at $263.53
    $264k
    48% of stake
  • Sep 25, 2025
    William R Shepard
    Director · bought 274 at avg $265.19
    $73k
    0.1% of stake
  • Sep 18, 202510b5-1 plan
    Jonathan L Marcus
    Sr MD General Counsel · sold 392 at $262.00
    $103k
    4.8% of stake
  • Sep 16, 202510b5-1 plan
    Jonathan L Marcus
    Sr MD General Counsel · sold 376 at $258.96
    $97k
    4.4% of stake
  • Sep 16, 2025No plan
    Timothy Francis McCourt
    Sr MD Global Head Equity & FX · sold 379 at $259.83
    $98k
    3.8% of stake
  • Aug 26, 2025No plan
    Sunil Cutinho
    Chief Information Officer · sold 11,896 at avg $271.47
    $3.23M
    41% of stake
  • Jun 25, 2025
    William R Shepard
    Director · bought 267 at avg $270.53
    $72k
    0.1% of stake
  • Jun 10, 2025No plan
    Charles P Carey
    Director · sold 500 at avg $265.35
    $133k
    9.0% of stake
  • May 22, 2025No plan
    Daniel G Kaye
    Director · sold 500 at $282.42
    $141k
    12% of stake
  • May 20, 202510b5-1 plan
    Jonathan L Marcus
    Sr MD General Counsel · sold 390 at $277.50
    $108k
    5.5% of stake
  • May 19, 2025No plan
    Phyllis M Lockett
    Director · sold 1,060 at $277.88
    $295k
    25% of stake
  • May 15, 2025No plan
    Martin J Gepsman
    Director · sold 300 at $273.17
    $82k
    1.2% of stake
  • May 15, 2025No plan
    Charles P Carey
    Director · sold 3,000 at $272.56
    $818k
    35% of stake
  • May 5, 2025No plan
    Derek Sammann
    Sr MD Gl Hd Commodities Mkts · sold 4,650 at avg $280.61
    $1.3M
    8.6% of stake
  • Apr 29, 2025No plan
    Dennis Suskind
    Director · sold 1,000 at $271.28
    $271k
    26% of stake
  • Apr 24, 2025 – Apr 25, 2025No plan
    Larry G Gerdes
    Director · sold 4,000 at avg $265.11
    $1.06M
    9.8% of stake
  • Mar 26, 2025
    William R Shepard
    Director · bought 274 at avg $262.62
    $72k
    0.1% of stake
  • Mar 14, 2025No plan
    Deborah J Lucas
    Director · sold 1,500 at $256.95
    $385k
    31% of stake
  • Mar 13, 2025No plan
    Howard J Siegel
    Director · sold 10,000 at $260.00
    $2.6M
    13% of stake
  • Mar 11, 2025No plan
    Terrence A Duffy
    Chairman and CEO · sold 30,000 at $259.18
    $7.78M
    36% of stake
  • Mar 3, 2025No plan
    Suzanne Sprague
    COO & Global Head of Clearing · sold 1,500 at $256.83
    $385k
    16% of stake
  • Feb 27, 2025No plan
    Hilda Harris Piell
    Sr MD & Chief HR Officer · sold 3,984 at $250.47
    $998k
    13% of stake
  • Feb 13, 2025No plan
    Ken Vroman
    Chief Transformation Officer · sold 5,066 at $250.00
    $1.27M
    23% of stake
How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch CME, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: Security & Commodity Brokers, Dealers, Exchanges & Services

Spot a number that looks wrong? Check it in CME's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing CME

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.